Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Restoration of BECN1/Beclin 1-dependent autophagy and depletion of SQSTM1/p62 by genetic manipulation or autophagy-stimulatory proteostasis regulators, such as cystamine, have positive effects on mouse models of human cystic fibrosis (CF). These measures rescue the functional expression of the most frequent pathogenic CFTR mutant, F508del, at the respiratory epithelial surface and reduce lung inflammation in Cftr(F508del) homozygous mice. Cysteamine, the reduced form of cystamine, is an FDA-approved drug. Here, we report that oral treatment with cysteamine greatly reduces the mortality rate and improves the phenotype of newborn mice bearing the F508del-CFTR mutation. Cysteamine was also able to increase the plasma membrane expression of the F508del-CFTR protein in nasal epithelial cells from F508del homozygous CF patients, and these effects persisted for 24 h after cysteamine withdrawal. Importantly, this cysteamine effect after washout was further sustained by the sequential administration of epigallocatechin gallate (EGCG), a green tea flavonoid, both in vivo, in mice, and in vitro, in primary epithelial cells from CF patients. In a pilot clinical trial involving 10 F508del-CFTR homozygous CF patients, the combination of cysteamine and EGCG restored BECN1, reduced SQSTM1 levels and improved CFTR function from nasal epithelial cells in vivo, correlating with a decrease of chloride concentrations in sweat, as well as with a reduction of the abundance of TNF/TNF-alpha (tumor necrosis factor) and CXCL8 (chemokine [C-X-C motif] ligand 8) transcripts in nasal brushing and TNF and CXCL8 protein levels in the sputum. Altogether, these results suggest that optimal schedules of cysteamine plus EGCG might be used for the treatment of CF caused by the F508del-CFTR mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses
Vandenberg, L. N., Colborn, T., Hayes, T. B., Heindel, J. J., Jacobs, D. R., Lee, D.-H., Shioda, T., Soto, A. M., vom Saal, F. S., Welshons, W. V., et al. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1050 · Cited by 3,209 · cited 1×
“However, the use of genistein in CF therapy is limited due to its undesirable effects on the immune and endocrine systems.(41,42) In an attempt to avoid the decline of rescued PM-resident F508del-CFTR after cysteamine washout, we tested the effects of another flavonoid, the green tea-derived epigallocatechin gallate (…”
BackgroundGibson, L. E., & Cooke, R. E. (1959) · Pediatrics · doi:10.1542/peds.23.3.545 · Cited by 1,434 · cited 2×
“Spirometry was performed in all CF patients according to American Thoracic Society guidelines.67 Sweat chloride values were obtained by quantitative pilocarpine iontophoresis according to the standardized protocol of Gibson and Cooke.68 Five adult non-CF healthy volunteers underwent nasal brushing at each time at whic…”
MethodCorrection of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
CFTR Function and Prospects for Therapy
Riordan, J. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142532 · Cited by 610 · cited 1×
“phe508delCFTR, commonly known as F508del-CFTR (categorized in class II), accounts for about 70% of CFTR loss-of-function mutations and is present in approximately 90% of CF patients worldwide.(3,9) Due to its misfold, F508del-CFTR protein does not reach the plasma membrane (PM) and is prematurely degraded.”
BackgroundLuciani, A., Villella, V. R., Esposito, S., Brunetti-Pierri, N., Medina, D., Settembre, C., Gavina, M., Pulze, L., Giardino, I., Pettoello-Mantovani, M., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2090 · Cited by 467 · cited 10×
“S7).(26) These effects were largely lost after 48 h of cysteamine withdrawal, unless EGCG was added to the system (Fig.”
BackgroundMethodInfluentialSelf-citationPeripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane
Okiyoneda, T., Barrière, H., Bagdány, M., Rabeh, W. M., Du, K., Höhfeld, J., Young, J. C., & Lukacs, G. L. (2010) · Science · doi:10.1126/science.1191542 · Cited by 408 · cited 1×
“Although F508del-CFTR can be rescued at the PM by CFTR correctors,(6) this mutant CFTR protein is unstable at the cell surface and rapidly redirected from endosomal recycling towards lysosomal delivery and degradation.(6,10,11) Despite of the mild gating defect linked to an altered protein conformation, F508del-CFTR a…”
BackgroundLukacs, G. L., Chang, X. B., Bear, C., Kartner, N., Mohamed, A., Riordan, J. R., & Grinstein, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80582-1 · Cited by 387
Cited by
Ponpuak, M., Mandell, M. A., Kimura, T., Chauhan, S., Cleyrat, C., & Deretic, V. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.04.016 · Cited by 506
Progress in therapies for cystic fibrosis
De Boeck, K., & Amaral, M. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00023-0 · Cited by 451
How autophagy controls the intestinal epithelial barrier
Foerster, E. G., Mukherjee, T., Cabral-Fernandes, L., Rocha, J. D. B., Girardin, S. E., & Philpott, D. J. (2022) · Autophagy · doi:10.1080/15548627.2021.1909406 · Cited by 397
Vij, N., Chandramani-Shivalingappa, P., Van Westphal, C., Hole, R., & Bodas, M. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00110.2016 · Cited by 329
Autophagy: a druggable process that is deregulated in aging and human disease
Kroemer, G. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78652 · Cited by 318
Self-citation
Metadata
- Authors
- Stefano, D. D., Villella, V. R., Esposito, S., Tosco, A., Sepe, A., Gregorio, F. D., Salvadori, L., Grassia, R., Leone, C. A., Rosa, G. D., Maiuri, M. C., Pettoello-Mantovani, M., Guido, S., Bossi, A., Zolin, A., Venerando, A., Pinna, L. A., Mehta, A., Bona, G., Kroemer, G., Maiuri, L., & Raia, V.
- Venue
- Autophagy
- Publisher
- Informa UK Limited
- Published
- 2014-11-02
- Volume
- 10
- Issue
- 11
- Pages
- 2053-2074
- ISSN
- 1554-8627 (ISSN-L)
- 1554-8635
- OpenAlex
- W2147285875
- Cited by
- 148
- References
- 8
- FWCI
- 15.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. https://app.cochat.ai/papers/10.4161/15548627.2014.973737
- The paper
- Stefano, D. D., Villella, V. R., Esposito, S., Tosco, A., Sepe, A., Gregorio, F. D., Salvadori, L., Grassia, R., Leone, C. A., Rosa, G. D., Maiuri, M. C., Pettoello-Mantovani, M., Guido, S., Bossi, A., Zolin, A., Venerando, A., Pinna, L. A., Mehta, A., Bona, G., . . . Raia, V. (2014). Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy. https://doi.org/10.4161/15548627.2014.973737
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.